3.
Summary of additional lesions detected by 68Ga PSMA PET/CT, and the influence on subsequent treatment
| Site of disease | Number of
patients (n) |
Number of additional lesions | Impact on management | ||||||||||||
| Prostate bed RT only to WPRT + HT | Switch to palliative HT (polymetastatic) | SBRT to metastases (oligometastatic; < 5 lesions) | |||||||||||||
| Overall 33 (of 44 patients with positive scan) | Overall 106
(of 175) |
Overall | PSA≤2.0 (ng/mL) | PSA>2.0 (ng/mL) | Overall | PSA<2.0 (ng/mL) | PSA>2.0 (ng/mL) | Overall | PSA<2.0 (ng/mL) | PSA>2.0 (ng/mL) | |||||
| RT, radiotherapy; WPRT, whole pelvic radiotherapy; HT, hormonal therapy; SBRT, stereotactic body radiotherapy; PSA, prostate specific antigen. | |||||||||||||||
| Locoregional
only |
18 | 32 (of 38) | |||||||||||||
| Prostate
bed |
8 | 11 | |||||||||||||
| Nodes+/-
prostate bed |
10 | 21 | 10 | 4 | 6 | ||||||||||
| Distant | 15 | 74 (of 137) | 8 | 6 | 2 | 7 | 5 | 2 | |||||||
| Nodes only | 3 | 10 | 1 | ||||||||||||
| Skeletal
only |
7 | 32 | 4 | ||||||||||||
| Nodes +
skeletal |
2 | 19 | 0 | ||||||||||||
| Visceral | 3 | 13 | 1 | ||||||||||||